Publication: Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.
Issued Date
2021-01-01
Resource Type
ISSN
2398502X
Other identifier(s)
2-s2.0-85113914271
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Wellcome Open Research. Vol.6, (2021)
Suggested Citation
Paulina Tindana, Freek de Haan, Olugbenga Ayodeji Mokuolu, Rosemonde Guissou, Oladimeji Akeem Bolarinwa, Jean Bosco Ouedraogo, Fatoumata Tou, Wouter P.C. Boon, Ellen H.M. Moors, Arjen M. Dondorp, Mehul Dhorda, Chanaki Amaratunga, Phaik Yeong Cheah Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.. Wellcome Open Research. Vol.6, (2021). doi:10.12688/wellcomeopenres.16065.1 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/76340
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.
Abstract
Introduction: According to the World Malaria Report 2019, Africa accounts for 94% of the global malaria deaths. While malaria prevalence and mortality have declined over the years, recent reports suggest that these gains may stand the risk of being reversed if resistance to Artemisinin Combination Therapies (ACTs) spreads from Southeast Asia to Africa. Efforts are being made to develop new treatments that will address the looming threat of ACT resistance, including the development of triple artemisinin combination therapies (TACTs). The proposed study seeks to explore the views of stakeholders on the key ethical, regulatory and market-related issues that should be considered in the potential introduction of triple artemisinin combination therapies (TACTs) in Africa. Methods: The study employed qualitative research methods involving in-depth interviews and focus group discussions (FGDs) with stakeholders, who will be directly affected by the potential deployment of triple artemisinin combination treatments, as regulators, suppliers and end-users. Participants will be purposively selected and will include national regulatory authorities, national malaria control programs, clinicians, distributors and retailers as well as community members in selected districts in Burkina Faso and Nigeria. Discussion: The proposed study is unique in being one of the first studies that seeks to understand the ethical, social, regulatory and market position issues prior to the development of a prospective antimalarial medicine.